(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally...
Stats | |
---|---|
Dagens volum | 1.79M |
Gjennomsnittsvolum | 1.68M |
Markedsverdi | 0.00 |
EPS | £0.0264 ( 2020-09-29 ) |
Last Dividend | £5.46 ( 2021-12-02 ) |
Next Dividend | £0 ( N/A ) |
P/E | 0.410 |
ATR14 | £0 (0.00%) |
Clinigen Group PLC Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
ARE.L | 0.952 |
3USS.L | 0.942 |
3ULS.L | 0.939 |
XPD.L | 0.936 |
MNZS.L | 0.93 |
PBLT.L | 0.925 |
GAW.L | 0.91 |
GPH.L | 0.891 |
IGE.L | 0.878 |
AIBG.L | 0.876 |
10 Mest negative korrelasjoner | |
---|---|
YGEN.L | -0.965 |
DNM.L | -0.942 |
ECHO.L | -0.941 |
FRG.L | -0.932 |
EXR.L | -0.932 |
3NGL.L | -0.931 |
SIXH.L | -0.925 |
GIF.L | -0.921 |
VCAP.L | -0.911 |
MAST.L | -0.911 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Clinigen Group PLC Økonomi
Annual | 2021 |
Omsetning: | £523.60M |
Bruttogevinst: | £197.90M (37.80 %) |
EPS: | £0.233 |
FY | 2021 |
Omsetning: | £523.60M |
Bruttogevinst: | £197.90M (37.80 %) |
EPS: | £0.233 |
FY | 2020 |
Omsetning: | £504.30M |
Bruttogevinst: | £220.00M (43.62 %) |
EPS: | £0.103 |
FY | 2019 |
Omsetning: | £456.90M |
Bruttogevinst: | £182.30M (39.90 %) |
EPS: | £0.0400 |
Financial Reports:
No articles found.
Clinigen Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £0.600 | 2013-03-06 |
Last Dividend | £5.46 | 2021-12-02 |
Next Dividend | £0 | N/A |
Payout Date | 2022-01-04 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | £45.62 | -- |
Avg. Dividend % Per Year | 0.20% | -- |
Score | 3.07 | -- |
Div. Sustainability Score | 9.57 | |
Div.Growth Potential Score | 2.52 | |
Div. Directional Score | 6.04 | -- |
Year | Amount | Yield |
---|---|---|
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £5.60 | 0.64% |
2019 | £6.70 | 0.91% |
2020 | £7.61 | 0.83% |
2021 | £7.61 | 1.09% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TCAP.L | Dividend King | 2023-09-26 | Semi-Annually | 24 | 3.86% | |
KMR.L | Dividend King | 2023-09-21 | Semi-Annually | 6 | 6.14% | |
CEY.L | Dividend King | 2023-08-31 | Semi-Annually | 11 | 3.71% | |
RCOI.L | Dividend Knight | 2023-08-17 | Quarterly | 5 | 4.80% | |
GLEN.L | Dividend Knight | 2023-08-31 | Semi-Annually | 14 | 3.43% | |
ANP.L | Dividend Knight | 2023-11-09 | Semi-Annually | 16 | 1.14% | |
TTE.L | Dividend King | 2024-01-02 | Quarterly | 15 | 4.15% | |
MER.L | Dividend Knight | 2023-10-05 | Annually | 28 | 2.09% | |
CRST.L | Dividend Knight | 2023-09-21 | Annually | 11 | 3.17% | |
SAIN.L | Dividend King | 2023-08-10 | Quarterly | 52 | 1.59% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0579 | 1.500 | 8.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0284 | 1.200 | 9.05 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0679 | 1.500 | -0.357 | -0.535 | [0.1 - 1] |
payoutRatioTTM | 0.333 | -1.000 | 6.67 | -6.67 | [0 - 1] |
currentRatioTTM | 1.752 | 0.800 | 6.24 | 4.99 | [1 - 3] |
quickRatioTTM | 0.480 | 0.800 | -1.884 | -1.507 | [0.8 - 2.5] |
cashRatioTTM | 0.480 | 1.500 | 8.45 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.393 | -1.500 | 3.45 | -5.18 | [0 - 0.6] |
interestCoverageTTM | 5.00 | 1.000 | 9.26 | 9.26 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.348 | 2.00 | 9.88 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.130 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.937 | -1.500 | 6.25 | -9.38 | [0 - 2.5] |
grossProfitMarginTTM | 0.378 | 1.000 | 7.03 | 7.03 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.112 | 1.000 | 9.77 | 9.77 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.108 | 1.000 | -0.511 | -0.511 | [0.2 - 2] |
assetTurnoverTTM | 0.491 | 0.800 | -0.0576 | -0.0460 | [0.5 - 2] |
Total Score | 9.57 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.63 | 1.000 | 6.10 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0679 | 2.50 | -0.229 | -0.535 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.130 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.348 | 2.00 | 9.88 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.333 | 1.500 | 6.67 | -6.67 | [0 - 1] |
pegRatioTTM | -48.27 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0863 | 1.000 | -0.342 | 0 | [0.1 - 0.5] |
Total Score | 2.52 |
Clinigen Group PLC
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.